Clinical trial
Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for…
NCT00110695 · NSABP Foundation Inc, Other · Completed
Key facts
| NCT number | NCT00110695 |
|---|---|
| Title | Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer |
| Official title | A Phase 2 Study of Neoadjuvant Chemotherapy With Sequential Weekly Nanoparticle Albumin Bound Paclitaxel (Abraxane) Followed by 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) in Locally Advanced Breast Cancer |
| Lead sponsor | NSABP Foundation Inc, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Nanoparticle albumin bound paclitaxel followed by FEC |
| Enrollment | 66 |
| Start date | Apr 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Jul 1, 2008 |
| First posted | May 13, 2005 |
| Last update posted | Mar 26, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: